A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature ( blood vessels) of cancer tumors causing central necrosis. [1]
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, plinabulin (NPI-2358) [2] [3] [4]
Phase III : DMXAA (ASA404).
References
- ^ Thorpe, Philip E. (2004). "Vascular Targeting Agents as Cancer Therapeutics" (PDF). Clinical Cancer Research. 10 (2): 415–427. doi: 10.1158/1078-0432.CCR-0642-03. PMID 14760060. S2CID 1739027.
- ^ "NPI-2358". clinicaltrials.gov.
- ^ Monica M. Mita; et al. (2010). "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin Cancer Res. 16 (23): 5892–5899. doi: 10.1158/1078-0432.CCR-10-1096. PMID 21138873.
- ^ Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature ( blood vessels) of cancer tumors causing central necrosis. [1]
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, plinabulin (NPI-2358) [2] [3] [4]
Phase III : DMXAA (ASA404).
References
- ^ Thorpe, Philip E. (2004). "Vascular Targeting Agents as Cancer Therapeutics" (PDF). Clinical Cancer Research. 10 (2): 415–427. doi: 10.1158/1078-0432.CCR-0642-03. PMID 14760060. S2CID 1739027.
- ^ "NPI-2358". clinicaltrials.gov.
- ^ Monica M. Mita; et al. (2010). "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin Cancer Res. 16 (23): 5892–5899. doi: 10.1158/1078-0432.CCR-10-1096. PMID 21138873.
- ^ Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58.
|
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |